An experimental Alzheimer’s treatment slowed mental decline in patients with early stages of the disease by 34 percent, the first evidence that a medication may be able to alter the course of the disease, according to research presented by scientists meeting in Boston on Monday. Reisa Sperling, HMS professor of neurology at Brigham and Women’s Hospital, led a study about a different experimental drug also presented Monday.
